Fractional exhaled nitric oxide and the peripheral blood eosinophil count as biomarkers of the response to mepolizumab in patients with severe eosinophilic asthma

Fractional exhaled nitric oxide and the peripheral blood eosinophil count as biomarkers of the response to mepolizumab in patients with severe eosinophilic asthma

Detalhes bibliográficos
Main Authors:	Shrimanker, R, Pavord, I, Price, R, Bradford, E, Keene, O, Yancey, S
Formato:	Conference item
Publicado em:	American Thoracic Society 2018

Registos relacionados

Prognostic and predictive value of blood eosinophil count, fractional exhaled nitric oxide and their combination in severe asthma: a post-hoc analysis
Por: Shrimanker, R, et al.
Publicado em: (2019)

Evaluation of potential continuation rules for mepolizumab treatment of severe eosinophilic asthma.
Por: Gunsoy, N, et al.
Publicado em: (2017)

Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
Por: Steven W. Yancey, et al.
Publicado em: (2019-09-01)

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
Por: Howell, I, et al.
Publicado em: (2024)

Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.
Por: Bel, E, et al.
Publicado em: (2014)

Mepolizumab treatment in patients with severe eosinophilic asthma.
Por: Ortega, H, et al.
Publicado em: (2014)

Glucocorticoids and mepolizumab in eosinophilic asthma.
Por: Bel, E, et al.
Publicado em: (2014)

Mepolizumab in refractory eosinophilic asthma.
Por: Pavord, I, et al.
Publicado em: (2010)

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
Por: Imran Howell, et al.
Publicado em: (2024-07-01)

Mepolizumab for eosinophilic COPD
Por: Sciurba, F, et al.
Publicado em: (2018)

Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations
Por: Price, D, et al.
Publicado em: (2019)

Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma
Por: Yancey, S, et al.
Publicado em: (2016)

Diagnostic possibility of the combination of exhaled nitric oxide and blood eosinophil count for eosinophilic asthma
Por: Jiang-Hua Li, et al.
Publicado em: (2021-08-01)

Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations
Por: David B. Price, et al.
Publicado em: (2019-08-01)

Mepolizumab, quality of life, and severe eosinophilic asthma.
Por: Pavord, I
Publicado em: (2017)

Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
Por: Ortega, H, et al.
Publicado em: (2016)

Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma
Por: Shrimanker, R, et al.
Publicado em: (2017)

Mepolizumab and exacerbations of refractory eosinophilic asthma.
Por: Haldar, P, et al.
Publicado em: (2009)

Biomarkers for severe eosinophilic asthma.
Por: Yancey, S, et al.
Publicado em: (2017)

Blood eosinophil depletion with mepolizumab, benralizumab and prednisolone in eosinophilic asthma
Por: Moran, AM, et al.
Publicado em: (2020)

Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab
Por: Ian D. Pavord, et al.
Publicado em: (2022-05-01)

Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo
Por: Shrimanker, R, et al.
Publicado em: (2017)

Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts
Por: Arian Ghassemian, et al.
Publicado em: (2021-01-01)

The peripheral blood eosinophil count as a biomarker of eosinophilic airway inflammation in patients with asthma and COPD. Experience from a single centre
Por: Shrimanker, R, et al.
Publicado em: (2017)

Mepolizumab for eosinophilic chronic obstructive pulmonary disease
Por: Pavord, I, et al.
Publicado em: (2017)

Association between fractional exhaled nitric oxide, sputum induction and peripheral blood eosinophil in uncontrolled asthma
Por: Jie Gao, et al.
Publicado em: (2018-05-01)

Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma
Por: Terufumi Shimoda, et al.
Publicado em: (2017-07-01)

Does a composite score combining peripheral blood eosinophils (PBE) and exhaled nitric oxide (FeNO) accurately predict a sputum eosinophilia?
Por: Connolly, CM, et al.
Publicado em: (2017)

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.
Por: Pavord, I, et al.
Publicado em: (2012)

Response to Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma and Atopic Phenotypes
Por: Prazma CM, et al.
Publicado em: (2021-06-01)

Both fractional exhaled nitric oxide and sputum eosinophil were associated with uncontrolled asthma
Por: Gao J, et al.
Publicado em: (2018-04-01)

Clinical usefulness of mepolizumab in severe eosinophilic asthma
Por: Menzella F, et al.
Publicado em: (2016-06-01)

Late breaking abstract - Dose-ranging study of mepolizumab in eosinophilic COPD
Por: Pavord, I, et al.
Publicado em: (2017)

Oral corticosteroid dose changes and impact on peripheral blood eosinophil counts in patients with severe eosinophilic asthma: a post hoc analysis
Por: Charlene M. Prazma, et al.
Publicado em: (2019-05-01)

Blood eosinophil phenotype during treatment with mepolizumab in patients with severe eosinophilic asthma
Por: Chio Sakai, et al.
Publicado em: (2024-07-01)

The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma.
Por: Berry, M, et al.
Publicado em: (2005)

Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis
Por: Wechsler, M, et al.
Publicado em: (2017)

Fractional exhaled nitric oxide and eosinophil count in induced sputum to guide the management of children with asthma: a cost-utility analysis
Por: Buendía, JA, et al.
Publicado em: (2022)

Fractional exhaled nitric oxide and eosinophil count in induced sputum to guide the management of children with asthma: a cost-utility analysis
Por: Jefferson Antonio Buendía, et al.
Publicado em: (2022-06-01)

Treatment Resistance in Severe Asthma Patients With a Combination of High Fraction of Exhaled Nitric Oxide and Low Blood Eosinophil Counts
Por: Yuki Hoshino, et al.
Publicado em: (2022-04-01)